Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Pharmaceutical TechnologyNovo Nordisk's Wegovy pill is already providing financial fuel in the company's bid to catch Eli Lilly.Metabolic & GLP-1Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) Pharmaceutical Technology Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly. Metabolic & GLP-1 Read full story Post navigation Previous: Angelini inks $4.1B Catalyst buy to enter US rare disease marketNext: Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq Related Stories Commercial Novo hikes guidance on Wegovy pill’s fast sales start pharminent May 6, 2026 Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026 Commercial Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat pharminent May 5, 2026
